Robert Hollamby
Directeur/Membre du Conseil chez Videregen Ltd.
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Stephen Bloor | M | - |
Videregen Ltd.
Videregen Ltd. BiotechnologyHealth Technology Videregen Ltd. operates a regenerative medicine company created to address the chronic shortage of organs for transplantation in the field of tissue decellularisation, regenerative technologies and translation from laboratory to market. Its platform technology uses decellularised organ scaffolds seeded with the patient’s own cells to create non-immunogenic, regenerative bespoke organ replacements. The company was founded by Stephen Bloor in 2011 and is headquartered in Liverpool, The United Kingdom. | 13 ans |
Martin Hunt | M | 66 |
Videregen Ltd.
Videregen Ltd. BiotechnologyHealth Technology Videregen Ltd. operates a regenerative medicine company created to address the chronic shortage of organs for transplantation in the field of tissue decellularisation, regenerative technologies and translation from laboratory to market. Its platform technology uses decellularised organ scaffolds seeded with the patient’s own cells to create non-immunogenic, regenerative bespoke organ replacements. The company was founded by Stephen Bloor in 2011 and is headquartered in Liverpool, The United Kingdom. | - |
Douglas Quinn | M | 69 |
Videregen Ltd.
Videregen Ltd. BiotechnologyHealth Technology Videregen Ltd. operates a regenerative medicine company created to address the chronic shortage of organs for transplantation in the field of tissue decellularisation, regenerative technologies and translation from laboratory to market. Its platform technology uses decellularised organ scaffolds seeded with the patient’s own cells to create non-immunogenic, regenerative bespoke organ replacements. The company was founded by Stephen Bloor in 2011 and is headquartered in Liverpool, The United Kingdom. | - |
Marc d'Abbadie | M | - |
Videregen Ltd.
Videregen Ltd. BiotechnologyHealth Technology Videregen Ltd. operates a regenerative medicine company created to address the chronic shortage of organs for transplantation in the field of tissue decellularisation, regenerative technologies and translation from laboratory to market. Its platform technology uses decellularised organ scaffolds seeded with the patient’s own cells to create non-immunogenic, regenerative bespoke organ replacements. The company was founded by Stephen Bloor in 2011 and is headquartered in Liverpool, The United Kingdom. | - |
Graphique Relationnel
Relation dans plusieurs entreprises
Statistiques
Pays | Relations | % du total |
---|---|---|
Royaume-Uni | 4 | 100,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Robert Hollamby
- Réseau Personnel